Product Images Terazosin
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Terazosin NDC 62135-461 by Chartwell Rx, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
image description - terazosin cap usp 10mg 90 bot lab
This text contains information about a medication called "Terazosi". It is in capsule form and is available in a bottle with 90 capsules. The NDC number for the medication is 62135-461-90. The website "www.chartwellpharma.com/our-products/" is mentioned as a place to print patient information about this medication.*
image description - terazosin cap usp 1mg 90 bot lab
This seems to be a description of a medication called Terazosin in capsule form. The NDC number mentioned is 62135-458-90 and the medication is specifically for prescription use only. The text also indicates that patients can find more information about the product at www.chertwelpharma.com.*
image description - terazosin cap usp 2mg 90 bot lab
This text contains some product information about Terazosin capsules, USP. The NDC code and prescription use are indicated. It also provides the website of the company, Chartwell Pharma, where patient information is available. Some characters are not readable, but the text seems to be a product label or description.*
image description - terazosin cap usp 5mg 90 bot lab
This is a product label for capsules of Terazosin, a medication that helps to relax the muscles in the prostate and bladder neck, making it easier to urinate. It is available only with a prescription.*
image description - terazosin cap usp fig 1
This is a figure from a study comparing the effects of a placebo and a drug called Terazosin on the symptoms and peak flow rate of individuals. The figure shows the mean change in total symptom score and mean increase in peak flow rate from baseline after a month of treatment. The study included 55 individuals in the placebo group and 52 individuals in the Terazosin group. The results show that Terazosin was statistically significant in improving these measures compared to the placebo group at a significance level of p < 0.05.*
image description - terazosin cap usp fig 2
The text describes a figure showing the mean change in a total symptom score over time in a long-term, non-placebo controlled study involving 494 participants. The figure shows the mean change from baseline at different time points up to 30 months, with a significant improvement observed from baseline.*
image description - terazosin cap usp fig 3
The image shows the mean change in peak flow rate from baseline for a long-term, non-placebo controlled study involving 494 participants. The study lasted for 30 months and the results indicate a statistically significant improvement in peak flow rate compared to baseline.*
image description - terazosin cap usp structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.